BrachySciences Only Company to Offer All Three Isotopes for Low Dose Rate Prostate Brachytherapy

OXFORD, Conn.--(BUSINESS WIRE)--BrachySciences, the leader in providing innovative medical devices for the treatment of early stage prostate cancer, has announced a distribution agreement with IsoRay Inc., manufacturer of Proxcelan™, the only Cesium-131 radioactive source available for brachytherapy. By adding the unique Cesium-131 source to its distribution portfolio of Advantage Iodine-125™ and the TheraSeed® Palladium-103 device, BrachySciences is now the only company capable of providing all three radioactive isotopes used in low dose rate (LDR) prostate brachytherapy.